Frontiers in Genetics (Nov 2023)

Identification and validation of N6-methyladenosine (m6A)-related lncRNAs signature for predicting the prognosis of laryngeal carcinoma, especially for smoking patients

  • Yuqing Chen,
  • Yuqing Chen,
  • Yuqing Chen,
  • Chenyu Chen,
  • Chenyu Chen,
  • Chenyu Chen,
  • Gufeng Gao,
  • Chaojun Zeng,
  • Chaojun Zeng,
  • Chaojun Zeng,
  • Zhifeng Chen,
  • Zhifeng Chen,
  • Zhifeng Chen,
  • Gongbiao Lin,
  • Gongbiao Lin,
  • Gongbiao Lin,
  • Guangnan Yao,
  • Guangnan Yao,
  • Guangnan Yao,
  • Shenqing Nian,
  • Shenqing Nian,
  • Shenqing Nian,
  • Xihang Chen,
  • Xihang Chen,
  • Xihang Chen,
  • Simin Weng,
  • Simin Weng,
  • Simin Weng,
  • Xi Gu,
  • Xi Gu,
  • Xi Gu,
  • Chang Lin,
  • Chang Lin,
  • Chang Lin

DOI
https://doi.org/10.3389/fgene.2023.1292164
Journal volume & issue
Vol. 14

Abstract

Read online

Laryngeal cancer (LC), a highly fatal tumor in the head and neck region, has been the focus of research in recent years. The study of LC has primarily focused on the role of long non-coding RNAs (lncRNAs) in regulating gene expression, as they have emerged as pivotal factors in this biological process. Additionally, a reversible RNA modification called N6-methyladenosine (m6A) has been observed to have a significant impact on gene expression as well. The purpose of this research is to investigate the impact of m6A-related lncRNAs on the prognosis of laryngeal squamous cell carcinoma (LSCC). Specifically, this investigation analyzed the m6A-related regulators’ patterns of expression and mutation, encompassing a total of 15 regulators. Drawing upon the expression levels of prognostic m6A-regulated lncRNAs, two distinct lncRNA clusters were identified. Further analysis revealed differentially expressed lncRNAs between these clusters. In addition to studying the expression of lncRNAs, the researchers also examined the distribution of clinical characteristics and the tumor microenvironment (TME) in relation to the identified lncRNA clusters. This provided valuable insights into potential associations between lncRNA expression patterns and the clinical features of LSCC. Through the establishment of a risk model associated with lncRNAs, we were able to further investigate their clinical features, prognosis, and immune status. Additionally, we conducted a separate analysis of LINC00528, a lncRNA associated with smoking, examining its expression, overall survival time, correlated mRNAs, and conducting enrichment of Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG), as well as determining the sensitivity of related drugs. RT-qPCR results also indicated an increase in LINC00528 expression among smoking LSCC patients. The findings suggest that a high expression level of LINC00528 in LSCC patients may lead to a more favorable prognosis, providing new insights for the management and treatment of LSCC patients, particularly those with high expression of LINC00528. Overall, this research sheds light on the prognostic impact of m6A-regulated lncRNAs in LSCC. The implications of these findings for the advancement of innovative therapeutic approaches for LSCC patients are noteworthy.

Keywords